Compare Levi Strauss & Co. (LEVI) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Levi Strauss & Co. vs Novo Nordisk A/S — how do they compare? Levi Strauss & Co. trades at $18.7 (market cap $7.31B), while Novo Nordisk A/S trades at $38.6 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 22.6× Levi Strauss & Co.'s market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Levi Strauss & Co. for 70 Days and Novo Nordisk A/S for 116 Days on average.
| LEVI | NVO | |
|---|---|---|
Market Cap | $7.31B | $165.31B |
Volume | 13,683,095 | 11,432,838 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.53 | $63.98 |
52-Week Low | $17.92 | $35.29 |
Typical Hold Time | 70 Days | 116 Days |
Enterprise Value | $8.86B | $179.56B |
Dividend Yield | 3.36% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Levi Strauss (LEVI) trades at $18.70, down 4.15% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 12.53 and consistent earnings beats, including Q3 2026 EPS of $0.48 versus $0.36 expected. Revenue for 2025 was $6.28 billion with a net income margin of 9.2%. Recent news highlights a new CFO appointment and positive analyst expectations for Q3 earnings.
The outlook is positive with a consensus price target of $29.00, implying 55% upside, supported by 78.95% analyst buy ratings. Risks include competitive pressures and recent cybersecurity incidents. The stock's valuation and earnings momentum present a compelling opportunity, though technical weakness warrants monitoring.
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
